ESO, CNIO and NRCO Conference on Familial Cancer

Chairs: R. Eeles, UK - W.D. Foulkes, CA - M. Robledo, ES - H. Vasen, NL


The ESO, CNIO and NRCO Conference on Familial Cancer aims to present the advances in this field from a multidisciplinary point of view. Familial cancer has become an important challenge for oncologists, geneticists, molecular biologists, and other professionals, due to its implications not only at individual but also at the familial and social level. Along the last years, new approaches have allowed to increase our knowledge about the genes responsible for familial cancer, as well as their biological functions, which is essential to find an appropriate treatment in each case. The next generation sequencing is extensively used in the search of causal mutations, but it represents a new challenge regarding the interpretation of variants, many of which must be classified as of unknown significance. Biannually the Conference brings together leading basic and translational researchers and clinicians involved in the diagnosis, treatment and follow-up of patients with familial cancer. These meetings help to establish connections among professionals that in turn promote progress in the understanding and treatment of these diseases. Besides the lectures from international experts, young scientists can present their work as short lectures and posters. This format aims to facilitate extensive discussion of current issues and stimulate new ideas.


LEARNING OBJECTIVES
• Selection criteria, landscape of breast and ovarian cancer genes, and clinical management
• Genetics and clinical management of hereditary colorectal cancer
• Therapeutic strategies in the era of personalized medicine
• Translating genetic risk factors to the surveillance and clinical management of prostate cancer
• Rare cancers: Gastric cancer, pancreatic cancer, tuberous sclerosis, Gorlin syndrome, PTEn and related diseases, multiple endocrine neoplasia type 1, among others
• Implications of applying next generation sequencing to the diagnosis


MAIN TOPICS
• Breast and ovarian cancer
• Colon and prostate cancer
• Rare cancers
• Implications of applying next generation sequencing to the diagnosis

In cooperation with:

ORGANISING SECRETARIAT
European School of Oncology
Via Turati, 29
20121 Milan - Italy
Tel: +39 02 8546 4523+39 02 8546 4523
Fax: +39 02 8546 4545

Organisation
Daniela Mengato (dmengato@eso.net)

Registrations
Laura Richetti (lrichetti@eso.net)


VENUE
Ateneo de Madrid
Calle del Prado 21, Madrid, Spain
www.ateneodemadrid.com


OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.


BADGE
The badge is the only official evidence of registration and should be worn at all times during the event. Loss of badge causes loss of registration.


INSURANCE
The organisers bears no responsibility for ontoword events in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance coverage.


CME ACCREDITATION CERTIFICATES
Participants will be entitled to receive a certificate of attendance at the close of the event by completing and submitting the on-line evaluation questionnaire.
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 11 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.


SPONSORS
ESO wishes to extend its appreciation to the sponsors for having granted their participation and support to the conference:

FACULTY
A. Antoniou, University of Cambridge, UK
S. Aretz, Institute of Human Genetics, University of Bonn, DE
J. Benítez, Centro Nacional de Investigaciones Oncólogicas (CNIO), Madrid, ES
I. Blanco, Hospital Germans Trias i Pujol, Barcelona, ES
F. Carneiro, Ipatimub-Institute of Molecular Pathology and Immunology, University of Porto, PT
P. Devilee, Leiden University Medical Centre, NL
R. Eeles, NHS Trust and the Institute for Cancer Research, Sutton, UK
W.D. Foulkes, Lady Davis Institute for Medical Research, Montreal, CA
E. Maher, University of Cambridge, UK
I. Márquez Rodas, Hospital General Universitario Gregorio Marañón, Madrid, ES
A. Osorio, Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, ES
N. Ratner, Children's Hospital Medical Center, Cincinnati, US
M. Robledo, Centro Nacional de Investigaciones Oncólogicas (CNIO), Madrid, ES
J.R. Sampson, Cardiff University and University Hospital of Wales, Cardiff, UK
S. Syngal, Dana Farber Cancer Institute, Boston, US
G.D. Valk, UMC Utrecht Cancer Center, NL
H. Vasen, Leiden University Medical Centre, NL
L. Walker, Oxford John Radcliffe Hospital, UK

 MAY 19

9:00		Welcome and introduction J. Benítez, ES
OPENING LECTURE
9:15		Hereditary cancer syndromes. Overview M. Robledo, ES
SESSION 1 - BREAST AND OVARIAN CANCER (PART I) Chair:  R. Eeles, UK
9:45		Selection criteria and clinical management L. Walker, UK
10:10		Landscape of breast cancer genes P. Devilee, NL
SHORT COMMUNICATIONS BY PARTICIPANTS Chair:  R. Eeles, UK
10:35		Molecular insights into the OGG1 gene, a modifier cancer risk in BRCA1 and BRCA2 mutations carriers Presenter: C. Benitez-Buelga, ES
10:50		Tumor suppressor C53 interacts with BRCA2, regulates DSB repair and drives breast and ovarian cancer prognosis Presenter: J. Minguillón, ES
11:05		Coffee-break and poster view
SESSION 1 - BREAST AND OVARIAN CANCER (PART II) Chair:  R. Eeles, UK
11:35		Ovarian cancer. Other genes beyond BRCAs A. Osorio, ES
12:00		Therapeutic strategies in the era of personalized medicine I. Márquez Rodas, ES
SHORT COMMUNICATIONS BY PARTICIPANTS Chair: H. Vasen, NL
12:25		Germline variants in DNA Interstrand-Cross limk repair genes may contribute to increased susceptibility for serrated polyposis Presenter: P. Silva, PT
12:40		Trusight Cancer panel testing in high risk patients at MMCI - Czech Republic Presenter: L. Foretova, CZ
12:55		Screening of p.L424V POLE mutation in a 600 patients polyposis cohort Presenter: D. Parraga, ES
13:15		Lunch and poster view
SESSION 2 - COLON AND PROSTATE CANCER Chair: H. Vasen, NL
15:30		Hereditary colorectal cancer. From dominant to recessive genetic models S. Aretz, DE
15:55		Clinical management of hereditary colorectal cancer syndromes S. Syngal, US
16:15		Prostate cancer. Translating genetic risk factors to the surveillance and clinical management R. Eeles, UK
16:40		Coffee-break and poster view
SESSION 3 - CLINICAL CASES Chair: I. Blanco, ES
17:15		POLE germline mutation p.(Val411Leu) causes a phenotype reminiscent of constitutional mismatch repair deficiency Presenter: K. Wimmer, AT
17:30		Germline 1100delC CHEK2 mutation in a proband diagnosed with adrenocortical carcinoma Presenter: D. Nowakowska, PL
17:45		Intrathoracic Malignant Peripheral Nerve Sheath Tumor in Neurofibromatosis Type I - a case report Presenter: S. Dagovic, RS
18:00		Variable penetrance in a family with Carney Complex - A six year old boy presenting with bilateral testicular tumours and a paternally inherited PRKAR1A splice site mutation Presenter: R. Bowden, UK
18:15		Individuals with multi-locus mutations in breast cancer predisposing genes Presenter: F. Fostira, GR
18:30		End of the session

 

 MAY 20

SESSION 4 - OTHER CANCER SYNDROMES I Chair: J. Benítez, ES
9:00		Genetic and clinical management of pancreatic cancer H. Vasen, NL
9:25		Multiple endocrine neoplasia type 1 G. Valk, NL
9:50		Germline DICER1 mutations. Phenotypic landscape W.D. Foulkes, CA
10:15		How is breast and ovarian cancer susceptibility modulated? A. Antoniou, UK
10:40		Coffee-break and poster view
SESSION 5 - OTHER CANCER SYNDROMES II Chair: W.D. Foulkes, CA
11:15		Hereditary gastric cancer F. Carneiro, PT
11:40		NF1, a RASopathy gene commonly involved in cancer N. Ratner, US
12:05		Hereditary renal cancer E. Maher, UK
12:30		Tuberous sclerosis as a model for targeted therapy J.R. Sampson, UK
SHORT ORAL COMMUNICATIONS BY PARTICIPANTS
12:55		Circulating free tumor DNA (cftDNA) as a novel biomarker for the early detection of cancer in familial pancreatic cancer families Presenter: J. Earl, ES
13:10		The role of VHL deficiency in differentiation and function of proximal tubule cells generated from patient-derived induced pluripotent stem cells Presenter: Y. Choudhury, SG
13:25		Lunch
SHORT ORAL COMMUNICATIONS BY PARTICIPANTS Chair: A. Osorio, ES
14:45		Hereditary truncating mutations in Fanconi anemia genes in BRCA1/2- negative breast and ovarian cancer families Presenter: L. Pérez-Cabornero, ES
15:00		Exome sequencing and analysis identifies activating familial Her2 germline mutation Presenter: S. Seshagiri, US
SESSION 6 - IMPLICATIONS OF APPLYING NEXT GENERATION SEQUENCING TO THE DIAGNOSIS AND ROUND TABLE DISCUSSION (15:15-15:45) Moderators: W.D. Foulkes, CA - P. Devilee, NL - I. Blanco, ES Topics to discuss:
		• Next Generation sequencing for diagnosis: WES/Whole genome versus gene panels. PRO   and CONS (W.D. Foulkes, CA)
		• VUS: a challenge at the bench (P. Devilee, NL)
		• Genetic counseling (I. Blanco, ES)
15:45		Open discussion
16:30		Closing remarks

 

ABSTRACT SUBMISSION

The abstract deadline is passed (6 March 2016)

Abstracts will be assessed for oral or poster presentation at the conference, and for publication on the event-dedicated website.
Participants are invited to submit an abstract on familial cancer, in one of the following categories:

• Diagnostic and prognostic biomarkers
• Case report
• Tumour biology
• Experimental and molecular therapeutics
• Approaches to cancer gene discovery

The acknowledgement of receipt of the abstract will immediately follow the submission.
The outcome will be notified to the first author who will be required to register to the conference (early registration deadline 30 March 2016).